Stockscreener 앱 받기
15.01
0.20%
-0.03
시간 외 거래:
15.01
전일 마감가:
$15.04
열려 있는:
$15.08
하루 거래량:
396.76K
Relative Volume:
0.60
시가총액:
$1.93B
수익:
$628.25M
순이익/손실:
$-78.55M
주가수익비율:
-19.49
EPS:
-0.77
순현금흐름:
$-29.73M
1주 성능:
-8.20%
1개월 성능:
+10.69%
6개월 성능:
+1.42%
1년 성능:
-22.67%
1일 변동 폭
$14.96
$15.26
1주일 범위
$14.96
$16.60
52주 변동 폭
$12.77
$21.22
Neogenomics Inc Stock (NEO) Company Profile
명칭
Neogenomics Inc
전화
(239) 768-0600
주소
9490 NEOGENOMICS WAY, FORT MYERS, FL
NEO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| NEO | 15.01 | 1.93B | 628.25M | -78.55M | -29.73M | -0.77 |
| TMO | 501.29 | 192.46B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 230.06 | 166.23B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 126.92 | 36.47B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 191.04 | 34.67B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 419.83 | 34.38B | 3.84B | 866.24M | 792.60M | 9.80 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-08-21 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-02-24 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-02-01 | 업그레이드 | Needham | Hold → Buy |
| 2022-08-26 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-08-22 | 다운그레이드 | Needham | Buy → Hold |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-03-29 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-29 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 재개 | Stephens | Overweight |
| 2021-12-16 | 개시 | Cowen | Outperform |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-02-25 | 재개 | Needham | Buy |
| 2021-02-25 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-12-11 | 재개 | BTIG Research | Buy |
| 2020-10-28 | 재확인 | Needham | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-08-28 | 개시 | Guggenheim | Buy |
| 2020-07-29 | 재확인 | Needham | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Buy |
| 2020-04-21 | 재개 | Stephens | Overweight |
| 2020-03-02 | 재개 | Craig Hallum | Buy |
| 2020-02-28 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-05-01 | 재확인 | Needham | Buy |
| 2019-03-29 | 재확인 | Needham | Buy |
| 2019-01-03 | 개시 | Needham | Buy |
| 2018-10-24 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 개시 | Leerink Partners | Outperform |
| 2018-05-02 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2017-08-24 | 개시 | Gabelli & Co | Buy |
| 2016-12-15 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Neogenomics Inc 주식(NEO)의 최신 뉴스
Los Angeles Capital Management LLC Invests $1.10 Million in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
T. Rowe Price Investment Management Reduces Stake in NeoGenomics Inc - GuruFocus.com
Janus Henderson Group PLC's Strategic Reduction in NeoGenomics I - GuruFocus.com
Felicia Williams Joins NeoGenomics Board of Directors - The Bakersfield Californian
NeoGenomics Appoints Former Macy's CFO Felicia Williams to Board of Directors | NEO Stock News - StockTitan
Trend Tracker for (NEO) - Stock Traders Daily
Pathological Examination Market to Grow with Leading Key - openPR
Creative Planning Purchases 7,004 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference - BioSpace
NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.89 Consensus Target Price from Brokerages - Defense World
NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know - MSN
NeoGenomics posts $18M net loss in Q3 - Gulfshore Business
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: NeoGenomics sees growth with NGS and new test launches By Investing.com - Investing.com South Africa
Earnings call: NeoGenomics sees growth with NGS and new test launches - Investing.com India
NeoGenomics' (NEO) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
NeoGenomics Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
NeoGenomics Reports Strong Q3 2024 Growth - TipRanks
NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say - MSN
NeoGenomics receives New York state approval for its solid tumor test - MSN
NeoGenomics: Q3 Earnings Snapshot - The Washington Post
NeoGenomics (NASDAQ:NEO) Updates FY 2024 Earnings Guidance - MarketBeat
NeoGenomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NeoGenomics Reports Third Quarter 2024 Results - Business Wire
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade - MSN
Emerald Mutual Fund Advisers Trust Sells 314,330 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
Allspring Global Investments Holdings LLC Reduces Stake in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics (NEO) Set to Announce Quarterly Earnings on Tuesday - Defense World
Blue Trust Inc. Boosts Stake in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics gains conditional approval for solid tumour assays in New York - Medical Device Network
NeoGenomics NGS tests gain New York State approval - Investing.com
NEONeoGenomics, Inc. Latest Stock News & Market Updates - StockTitan
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test - Business Wire
Clinical Laboratory Tests Market 2023-2031 | Latest Overview Analysis Report - InsightAce Analytic
Truist Financial Corp Sells 4,699 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics (NASDAQ:NEO) Shares Down 2.5%Should You Sell? - MarketBeat
Is NeoGenomics (NASDAQ:NEO) A Risky Investment? - Simply Wall St
Neogenomics Inc. (NEO) gets rating Resumed from Craig Hallum - Knox Daily
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 - BioSpace
Analytical Lens: Exploring Neogenomics Inc. (NEO)’s Financial Story Through Ratios - The Dwinnex
Check out these key findings about Neogenomics Inc. (NEO) - SETE News
Renaissance Technologies LLC Cuts Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
(NEO) Technical Data - Stock Traders Daily
Breast Cancer Liquid Biopsy Market is expected to Double Its Size - openPR
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
NEO (Neogenomics Inc.) may reap gains as insiders became active recently - Knox Daily
Neogenomics Inc. (NEO)’s results reveal risk - US Post News
Neogenomics Inc (NEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.04%
3.19%
자본화:
|
볼륨(24시간):